BACKGROUND: Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF), a high body mass index (BMI) appears to be beneficial. Approximately 50% of HF patients have a preserved left ventricular ejection fraction (HFPEF). However, there are few data regarding the relationship between BMI and outcomes in HFPEF. METHODS AND RESULTS:Baseline characteristics and cardiovascular outcomes were assessed in the 4109 patients (mean age, 72 years; mean follow-up, 49.5 months) in the Irbesartan in HF with Preserved Ejection Fraction (I-PRESERVE) trial. Based on the BMI distribution, 5 BMI categories were defined: <23.5, 23.5 to 26.4, 26.5 to 30.9, 31 to 34.9, and ≥35 kg/m(2). Most patients (71%) had a BMI ≥26.5, 21% had a BMI between 23.5 and 26.4, and 8% had a BMI <23.5 kg/m(2). Patients with higher BMI were younger, more often women, and more likely to have hypertension and diabetes and higher left ventricular ejection fraction. Patients with BMI of 26.5 to 30.9 kg/m(2) had the lowest rate for the primary composite outcome (death or cardiovascular hospitalization) and were used as reference group. After adjustment for 21 risk variables including age, sex, and N-terminal pro-brain natriuretic peptide, the hazard ratio for the primary outcome was increased in patients with BMI <23.5 (hazard ratio, 1.27; 95% confidence interval, 1.04 to 1.56; P=0.019) and in those with BMI ≥35 kg/m(2) (hazard ratio, 1.27; 95% confidence interval, 1.06 to 1.52; P=0.011) compared with the referent group. A similar relationship was found for all-cause mortality and for HF hospitalization. CONCLUSIONS: Obesity is common in HFPEF patients and is accompanied by multiple differences in clinical characteristics. Independent of other key prognostic variables, there was a U-shaped relationship, with the greatest rate of adverse outcomes in the lowest and highest BMI categories. CLINICAL TRIAL REGISTRATION- URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.
RCT Entities:
BACKGROUND:Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF), a high body mass index (BMI) appears to be beneficial. Approximately 50% of HF patients have a preserved left ventricular ejection fraction (HFPEF). However, there are few data regarding the relationship between BMI and outcomes in HFPEF. METHODS AND RESULTS: Baseline characteristics and cardiovascular outcomes were assessed in the 4109 patients (mean age, 72 years; mean follow-up, 49.5 months) in the Irbesartan in HF with Preserved Ejection Fraction (I-PRESERVE) trial. Based on the BMI distribution, 5 BMI categories were defined: <23.5, 23.5 to 26.4, 26.5 to 30.9, 31 to 34.9, and ≥35 kg/m(2). Most patients (71%) had a BMI ≥26.5, 21% had a BMI between 23.5 and 26.4, and 8% had a BMI <23.5 kg/m(2). Patients with higher BMI were younger, more often women, and more likely to have hypertension and diabetes and higher left ventricular ejection fraction. Patients with BMI of 26.5 to 30.9 kg/m(2) had the lowest rate for the primary composite outcome (death or cardiovascular hospitalization) and were used as reference group. After adjustment for 21 risk variables including age, sex, and N-terminal pro-brain natriuretic peptide, the hazard ratio for the primary outcome was increased in patients with BMI <23.5 (hazard ratio, 1.27; 95% confidence interval, 1.04 to 1.56; P=0.019) and in those with BMI ≥35 kg/m(2) (hazard ratio, 1.27; 95% confidence interval, 1.06 to 1.52; P=0.011) compared with the referent group. A similar relationship was found for all-cause mortality and for HF hospitalization. CONCLUSIONS:Obesity is common in HFPEF patients and is accompanied by multiple differences in clinical characteristics. Independent of other key prognostic variables, there was a U-shaped relationship, with the greatest rate of adverse outcomes in the lowest and highest BMI categories. CLINICAL TRIAL REGISTRATION- URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.
Authors: Francesca Bursi; Susan A Weston; Margaret M Redfield; Steven J Jacobsen; Serguei Pakhomov; Vuyisile T Nkomo; Ryan A Meverden; Véronique L Roger Journal: JAMA Date: 2006-11-08 Impact factor: 56.272
Authors: Stuart J Pocock; John J V McMurray; Joanna Dobson; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Marc A Pfeffer; Scott D Solomon; Stefan D Anker; Karl B Swedberg Journal: Eur Heart J Date: 2008-09-26 Impact factor: 29.983
Authors: Satish Kenchaiah; Stuart J Pocock; Duolao Wang; Peter V Finn; Leonardo A M Zornoff; Hicham Skali; Marc A Pfeffer; Salim Yusuf; Karl Swedberg; Eric L Michelson; Christopher B Granger; John J V McMurray; Scott D Solomon Journal: Circulation Date: 2007-07-16 Impact factor: 29.690
Authors: T Pischon; H Boeing; K Hoffmann; M Bergmann; M B Schulze; K Overvad; Y T van der Schouw; E Spencer; K G M Moons; A Tjønneland; J Halkjaer; M K Jensen; J Stegger; F Clavel-Chapelon; M-C Boutron-Ruault; V Chajes; J Linseisen; R Kaaks; A Trichopoulou; D Trichopoulos; C Bamia; S Sieri; D Palli; R Tumino; P Vineis; S Panico; P H M Peeters; A M May; H B Bueno-de-Mesquita; F J B van Duijnhoven; G Hallmans; L Weinehall; J Manjer; B Hedblad; E Lund; A Agudo; L Arriola; A Barricarte; C Navarro; C Martinez; J R Quirós; T Key; S Bingham; K T Khaw; P Boffetta; M Jenab; P Ferrari; E Riboli Journal: N Engl J Med Date: 2008-11-13 Impact factor: 91.245
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2014-11-24 Impact factor: 24.094
Authors: Kathryn Dryer; Mark Gajjar; Nikhil Narang; Margaret Lee; Jonathan Paul; Atman P Shah; Sandeep Nathan; Javed Butler; Charles J Davidson; William F Fearon; Sanjiv J Shah; John E A Blair Journal: Am J Physiol Heart Circ Physiol Date: 2018-02-09 Impact factor: 4.733
Authors: Tiffany M Powell-Wiley; Julius Ngwa; Selomie Kebede; Di Lu; Phillip J Schulte; Deepak L Bhatt; Clyde Yancy; Gregg C Fonarow; Michelle A Albert Journal: JACC Heart Fail Date: 2018-02-07 Impact factor: 12.035
Authors: Zhuo Zhao; Hao Wang; Jewell A Jessup; Sarah H Lindsey; Mark C Chappell; Leanne Groban Journal: Am J Physiol Heart Circ Physiol Date: 2014-01-10 Impact factor: 4.733
Authors: Selma F Mohammed; Barry A Borlaug; Véronique L Roger; Sultan A Mirzoyev; Richard J Rodeheffer; Julio A Chirinos; Margaret M Redfield Journal: Circ Heart Fail Date: 2012-10-17 Impact factor: 8.790
Authors: David P Kao; James D Lewsey; Inder S Anand; Barry M Massie; Michael R Zile; Peter E Carson; Robert S McKelvie; Michel Komajda; John J V McMurray; JoAnn Lindenfeld Journal: Eur J Heart Fail Date: 2015-08-06 Impact factor: 15.534
Authors: Dalane W Kitzman; Peter Brubaker; Timothy Morgan; Mark Haykowsky; Gregory Hundley; William E Kraus; Joel Eggebeen; Barbara J Nicklas Journal: JAMA Date: 2016-01-05 Impact factor: 56.272